BTK and lymphoma: Approximately half of patients with lymphoma struggle to produce effective SARS-CoV-2 antibodies [5], particularly those undergoing B cell depletion therapies such as anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase (BTK) inhibitor.